Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Phase 2

Completed

Conditions: Transfusion-dependent Anemia

Interventions: Drug: Deferasirox DT formulation
Drug: Deferasirox granule formulation

First Posted Date: 2015-05-06

Last Posted Date: 2024-03-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 224

Registration Number: NCT02435212

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey
🇺🇸
Weill Cornell Medical College SC -, New York, New York, United States
🇺🇸
Childrens Hospital at Montefiore, Bronx, New York, United States

and more 3 locations

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

Phase 1

Completed

Conditions: Normal Renal Function
Impaired Renal Function

Interventions: Drug: LEE011

First Posted Date: 2015-05-01

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT02431481

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇩🇪
Novartis Investigative Site, Berlin, Germany

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Phase 1

Completed

Conditions: ALK-positive Advanced Tumors

Interventions: Drug: ceritinib
Drug: warfarin
Drug: midazolam

First Posted Date: 2015-04-21

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT02422589

Locations: 🇺🇸
Cancer Therapy & Research Center UT Health Science Center SC-4, San Antonio, Texas, United States
🇺🇸
Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸
Karmanos Cancer Institute Oncology Department, Detroit, Michigan, United States

and more 1 locations

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Phase 3

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Ribociclib
Drug: Placebo
Drug: Fulvestrant

First Posted Date: 2015-04-21

Last Posted Date: 2023-11-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 726

Registration Number: NCT02422615

Locations: 🇺🇸
UCLA Medical Center ., Los Angeles, California, United States
🇺🇸
Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States
🇺🇸
UF Health Cancer Center at Orlando Health, Orlando, Florida, United States

and more 24 locations

Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients

Phase 2

Completed

Conditions: Hidradenitis Suppurativa (Acne Inversa)

Interventions: Drug: Placebo
Biological: CJM112

First Posted Date: 2015-04-20

Last Posted Date: 2022-07-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT02421172

Locations: 🇨🇭
Novartis Investigative Site, Zurich, Switzerland

Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol
Drug: Placebo

First Posted Date: 2015-04-16

Last Posted Date: 2017-07-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT02418468

Locations: 🇭🇰
Novartis Investigative Site, Hong Kong, Hong Kong

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Capmatinib

First Posted Date: 2015-04-10

Last Posted Date: 2024-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT02414139

Locations: 🇺🇸
University of California Irvine Medical Center Chao Family Chao Family Comp Cancer Center, Orange, California, United States
🇺🇸
University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
🇺🇸
Pacific Shores Medical Group SC, Long Beach, California, United States

and more 11 locations

Plaque Psoriasis Efficacy and Safety With Secukinumab

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: Secukinumab

First Posted Date: 2015-04-07

Last Posted Date: 2019-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16487

Registration Number: NCT02409667

Locations: 🇬🇧
Novartis Investigative Site, Harrogate, United Kingdom

Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag
Drug: Rabbit ATG
Drug: CsA

First Posted Date: 2015-03-31

Last Posted Date: 2019-07-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT02404025

Locations: 🇯🇵
Novartis Investigative Site, Tokyo, Japan

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Investigational Treatment
Drug: Active comparator

First Posted Date: 2015-03-31

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 82

Registration Number: NCT02404389

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy